Product Description
For Treatment of respiratory distress syndrome (RDS) in pre-term babies (Sourced from: https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/elifactant.pdf)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chiesi
Company Location: Europe
Company Founding Year: 1935
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn
Phase 1: Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Heart Failure, Chronic|Respiratory Insufficiency
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01651637 |
CCD-1011-PR-0059 | P1 |
Completed |
Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome |
2015-01-23 |
2020-08-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2011-001331-22 |
2011-001331-22 | P1 |
Completed |
Respiratory Insufficiency|Heart Failure, Chronic |
2015-01-23 |
2022-03-13 |
Treatments |
|
NCT02452476 |
CCD-05633AA1-02 | P2 |
Completed |
Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome |
2018-05-24 |
47% |
2021-06-24 |
Primary Endpoints|Treatments |